(NASDAQ: CV) Capsovision's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Capsovision's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast CV's revenue for 2025 to be $654,836,938, with the lowest CV revenue forecast at $654,836,938, and the highest CV revenue forecast at $654,836,938. On average, 1 Wall Street analysts forecast CV's revenue for 2026 to be $1,580,963,465, with the lowest CV revenue forecast at $1,580,963,465, and the highest CV revenue forecast at $1,580,963,465.
In 2027, CV is forecast to generate $2,474,348,144 in revenue, with the lowest revenue forecast at $2,474,348,144 and the highest revenue forecast at $2,474,348,144.